Disease activity and glucocorticoid tapering patterns in Japanese patients with systemic lupus erythematosus treated with anifrolumab: Post hoc analysis of the Japanese subpopulation of the TULIP-2 study
Modern Rheumatology · 2025
DOI: 10.1093/mr/roae105 ↗Kurz gefasst
Klinische Studie (Phase III) in der Zeitschrift Modern Rheumatology, 2025. Verfasst von Yoshiya Tanaka und 12 weiteren Autor:innen. Beteiligte Einrichtung: First Department of Internal Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Drug Tapering, Glucocorticoids, Lupus Erythematosus, Systemic. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Objectives
The aim of this study is to investigate the efficacy of anifrolumab in disease activity and glucocorticoid (GC) tapering patterns in Japanese patients with systemic lupus erythematosus (SLE).
Methods
We analysed disease activity and GC tapering in the Japanese subpopulation (anifrolumab, n = 24; placebo, n = 19) of the Treatment of Uncontrolled Lupus via the Interferon Pathway (TULIP-2) trial, which showed the efficacy and safety of anifrolumab in patients with moderate-to-severe active SLE.
Results
The percentage of patients who achieved a British Isles Lupus Assessment Group-based Composite Lupus Assessment response at Week 52 was greater in the anifrolumab group than in the placebo group [50.0% (12/24) vs 15.8% (3/19); P = .014]. Lupus low disease activity state (LLDAS) was achieved at Week 52 by 9/24 (37.5%) and 3/19 (15.8%) patients receiving anifrolumab and placebo, respectively. During the 52-week study period, in the anifrolumab vs placebo groups, 5/24 (20.8%) patients were in LLDAS ≥50% of the observed time vs 0/19 (0.0%), and 14/24 (58.3%) vs 6/19 (31.6%) patients were classified into favourable GC tapering patterns. Anifrolumab had an acceptable tolerability profile, consistent with the overall population.
Conclusions
In the Japanese subpopulation of the TULIP-2 trial, anifrolumab resulted in improvements in disease activity to those reported for the overall population, suggesting a beneficial effect for disease control.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- First Department of Internal Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan.
- Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Hokkaido, Japan.
- Immuno-Rheumatology Center, St. Luke's International Hospital, Tokyo, Japan.
- Department of Internal Medicine and Rheumatology, National Hospital Organization, Kyushu Medical Center, Fukuoka, Japan.
- Division of Hematology and Rheumatology, Tohoku Medical and Pharmaceutical University, Sendai, Miyagi, Japan.
- Rheumatic Disease Center, Kurashiki Medical Center, Okayama, Japan.
ORCID-Profile: Yoshiya Tanaka
Zitieren
APA
Tanaka, Y., Atsumi, T., Okada, M., Miyamura, T., Ishii, T., Nishiyama, S., Matsumura, R., Morishima, Y., Yamaguchi, Y., Abreu, G., Lindholm, C., Morand, E. F., & Takeuchi, T. (2025). Disease activity and glucocorticoid tapering patterns in Japanese patients with systemic lupus erythematosus treated with anifrolumab: Post hoc analysis of the Japanese subpopulation of the TULIP-2 study. Modern Rheumatology. https://doi.org/10.1093/mr/roae105
Vancouver
Tanaka Y, Atsumi T, Okada M, Miyamura T, Ishii T, Nishiyama S, et al. Disease activity and glucocorticoid tapering patterns in Japanese patients with systemic lupus erythematosus treated with anifrolumab: Post hoc analysis of the Japanese subpopulation of the TULIP-2 study. Modern Rheumatology. 2025. doi:10.1093/mr/roae105
BibTeX
@article{Tanaka2025,
author = {Tanaka, Yoshiya and Atsumi, Tatsuya and Okada, Masato and Miyamura, Tomoya and Ishii, Tomonori and Nishiyama, Susumu and Matsumura, Ryutaro and Morishima, Yosuke and Yamaguchi, Yoshiyuki and Abreu, Gabriel and Lindholm, Catharina and Morand, Eric F and Takeuchi, Tsutomu},
title = {Disease activity and glucocorticoid tapering patterns in Japanese patients with systemic lupus erythematosus treated with anifrolumab: Post hoc analysis of the Japanese subpopulation of the TULIP-2 study},
journal = {Modern Rheumatology},
year = {2025},
doi = {10.1093/mr/roae105}
}
EUVIMED